(MRNY) YieldMax MRNA Option Income - Overview
Etf: Options, Strategy, Non-Diversified, Defensive
Dividends
| Dividend Yield | 81.81% |
| Yield on Cost 5y | 9.36% |
| Yield CAGR 5y | -66.36% |
| Payout Consistency | 73.9% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 69.7% |
| Relative Tail Risk | -5.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -21.77 |
| Character TTM | |
|---|---|
| Beta | 1.059 |
| Beta Downside | 0.919 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.04% |
| CAGR/Max DD | -0.38 |
Description: MRNY YieldMax MRNA Option Income January 19, 2026
The YieldMax MRNA Option Income Strategy ETF (NYSE ARCA: MRNY) is a non-diversified, derivative-income ETF that focuses exclusively on Moderna Inc. (MRNA). Its advisor commits to maintaining exposure to MRNA regardless of market or economic conditions, while taking temporary defensive positions when adverse environments arise.
Key additional context: (1) Moderna’s revenue is heavily tied to its COVID-19 vaccine sales, which have shown a declining trend as global demand eases, making vaccine pipeline diversification a critical KPI. (2) The biotech sector’s valuation is highly sensitive to FDA approval cycles and biotech-specific interest-rate spreads, which can amplify the fund’s volatility. (3) As a non-diversified vehicle, MRNY’s concentration risk is reflected in a beta that typically exceeds 1.5 relative to the S&P 500, indicating amplified market movements.
For a deeper dive into the fund’s risk profile and performance metrics, you might explore ValueRay’s analytical tools.
What is the price of MRNY shares?
Over the past week, the price has changed by -8.72%, over one month by +30.97%, over three months by +45.77% and over the past year by +5.42%.
Is MRNY a buy, sell or hold?
What are the forecasts/targets for the MRNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 20.1 | 8.4% |
MRNY Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 90.4m USD (90.4m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 90.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 90.4m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.82% (E(90.4m)/V(90.4m) * Re(9.82%) + (debt-free company))
Discount Rate = 9.82% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)